Education
About Us
Working with TipRanks
Follow Us
Valerio Therapeutics (FR:ALVIO)
:ALVIO
Total Valuation
Valerio Therapeutics has a market cap or net worth of €70.55M. The enterprise value is €65.41M.
Market Cap€70.55M
Enterprise Value€65.41M
Share Statistics
Valerio Therapeutics has 499,448,300 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding499,448,300
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Valerio Therapeutics’s return on equity (ROE) is 2.68 and return on invested capital (ROIC) is -228.54%.
Return on Equity (ROE)2.68
Return on Assets (ROA)-1.33
Return on Invested Capital (ROIC)-228.54%
Return on Capital Employed (ROCE)40.41
Revenue Per Employee47.18K
Profits Per Employee-629.76K
Employee Count38
Asset Turnover0.10
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Valerio Therapeutics is ―. Valerio Therapeutics’s PEG ratio is -0.07.
PE Ratio―
PS Ratio6.44
PB Ratio-1.29
Price to Fair Value-1.29
Price to FCF-0.90
Price to Operating Cash Flow-2.37
PEG Ratio-0.07
Income Statement
In the last 12 months, Valerio Therapeutics had revenue of 1.79M and earned -23.93M in profits. Earnings per share was -0.16.
Revenue1.79M
Gross Profit1.28M
Operating Income-16.49M
Pretax Income-23.55M
Net Income-23.93M
EBITDA-12.06M
Earnings Per Share (EPS)-0.16
Cash Flow
In the last 12 months, operating cash flow was -9.23M and capital expenditures -386.00K, giving a free cash flow of -9.62M billion.
Operating Cash Flow-9.23M
Free Cash Flow-9.62M
Free Cash Flow per Share-0.02
Dividends & Yields
Valerio Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta-1.40
52-Week Price Change80.77%
50-Day Moving Average0.15
200-Day Moving Average0.09
Relative Strength Index (RSI)49.09
Average Volume (3m)1.36M
Important Dates
Valerio Therapeutics upcoming earnings date is Oct 29, 2025, During Market Hours (Confirmed).
Last Earnings DateJul 9, 2025
Next Earnings DateOct 29, 2025
Ex-Dividend Date―
Financial Position
Valerio Therapeutics as a current ratio of 0.25, with Debt / Equity ratio of -203.69%
Current Ratio0.25
Quick Ratio0.25
Debt to Market Cap1.12
Net Debt to EBITDA-1.02
Interest Coverage Ratio-52.68
Taxes
In the past 12 months, Valerio Therapeutics has paid 377.00K in taxes.
Income Tax377.00K
Effective Tax Rate-0.02
Enterprise Valuation
Valerio Therapeutics EV to EBITDA ratio is -1.97, with an EV/FCF ratio of -1.86.
EV to Sales13.27
EV to EBITDA-1.97
EV to Free Cash Flow-1.86
EV to Operating Cash Flow-1.91
Balance Sheet
Valerio Therapeutics has €2.64M in cash and marketable securities with €18.57M in debt, giving a net cash position of -€15.93M billion.
Cash & Marketable Securities€2.64M
Total Debt€18.57M
Net Cash-€15.93M
Net Cash Per Share-€0.03
Tangible Book Value Per Share-€0.13
Margins
Gross margin is -259.23%, with operating margin of -919.63%, and net profit margin of -1334.69%.
Gross Margin-259.23%
Operating Margin-919.63%
Pretax Margin-1313.61%
Net Profit Margin-1334.69%
EBITDA Margin-672.73%
EBIT Margin-1303.74%
Analyst Forecast
The average price target for Valerio Therapeutics is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target―
Price Target Upside―
Analyst Consensus―
Analyst Count0
Revenue Growth Forecast-3.12%
EPS Growth Forecast30.49%